NEO NeoGenomics, Inc.
NEO NeoGenomics, Inc.
Healthcare · Diagnostics & Research
Market read
POC $10.07 · VWAP $12.34 · +34.9% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 watchlist
NEO Price Structure
Loading timeframes…
Peers
Every watchlist NEO belongs to, members best 30-day change first — NEO highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported EPS $0.05 versus analyst consensus of $0.03 (+48.6%).
full note →Against street estimates
How NEO's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about NEO from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 11 days ago · Oct 6
- NeoGenomics (NEO) Stock Forecast & Price Prediction 2026–2030 | CoinCodex
- NeoGenomics, Inc. (NEO) Q2 FY2026 earnings call transcript
- NeoGenomics Q3FY26 Results: Revenue ~$209M, Guidance Reiterated
- NeoGenomics Reports Second Quarter 2026 Results
- NeoGenomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | MarketScreener
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
NEO research tape
57 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.